Table 2.
Adjusted Prevalence Estimates (Predictive Margins) of Penile Human Papillomavirus Infection Among Unvaccinated, Sexually Experienced Males, Stratified by Age and Number of Lifetime Sexual Partners
| HPV Type and Age Group | Adjusted HPV Prevalence, % (95% CI) | |
|---|---|---|
| Overall Male Population (n = 2495)a | Males Without a New Partner in the Past 12 mo (n = 2025)b | |
| 9-valent vaccine typec | ||
| Age 18–26 y | ||
| 1–5 LTSPs | 5.4 (2.1–8.6) | 5.7 (1.3–10.2) |
| >5 LTSPs | 15.6 (9.1–22.1) | 16.4 (5.8–26.9) |
| Age 27–45 y | ||
| 1–5 LTSPs | 6.2 (3.6–8.7) | 5.1 (2.9–7.3) |
| >5 LTSPs | 20.0 (16.6–23.3) | 18.8 (15.0–22.6) |
| Age 46–59 y | ||
| 1–5 LTSPs | 7.3 (3.0–11.5) | 6.2 (2.6–9.8) |
| >5 LTSPs | 17.6 (13.6–21.7) | 14.0 (9.7–18.3) |
| High-risk typed | ||
| Age 18–26 y | ||
| 1–5 LTSPs | 11.9 (6.9–17.0) | 10.6 (4.3–16.9) |
| >5 LTSPs | 33.6 (24.9–42.4) | 37.4 (24.5–50.2) |
| Age 27–45 y | ||
| 1–5 LTSPs | 13.7 (8.6–18.7) | 11.9 (7.6–16.2) |
| >5 LTSPs | 30.5 (27.3–33.8) | 29.0 (25.3–32.8) |
| Age 46–59 y | ||
| 1–5 LTSPs | 15.9 (10.9–20.9) | 14.2 (9.6–18.9) |
| >5 LTSPs | 26.9 (22.4–31.3) | 23.3 (19.3–27.4) |
| Any typee | ||
| Age 18–26 y | ||
| 1–5 LTSPs | 24.2 (18.4–30.1) | 21.7 (13.7–29.6) |
| >5 LTSPs | 51.7 (43.3–60.1) | 55.7 (44.8–66.6) |
| Age 27–45 y | ||
| 1–5 LTSPs | 27.9 (20.5–35.2) | 26.3 (19.4–33.3) |
| >5 LTSPs | 56.1 (51.7–60.5) | 55.6 (50.4–60.9) |
| Age 46–59 y | ||
| 1–5 LTSPs | 30.9 (23.2–38.7) | 29.6 (21.9–37.4) |
| >5 LTSPs | 56.8 (51.3–62.4) | 52.2 (46.7–57.7) |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; LTSP, lifetime sexual partner.
aFor each HPV outcome, adjusted prevalence estimates (predictive margins) of HPV detection were calculated by weighted multivariable logistic regression models, which included adjustment for race/ethnicity, marital status, cigarette smoking status, lifetime number of sexual partners (continuous), and report of a new sexual partnership in the past 12 months.
bFor each HPV outcome, adjusted prevalence estimates (predictive margins) of HPV detection were calculated by weighted multivariable logistic regression models, which included adjustment for race/ethnicity, marital status, cigarette smoking status, and lifetime number of sexual partners (continuous).
cNine-valent vaccine types: 6, 11, 16, 18, 31, 33, 45, 52, 58.
dHigh-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
eAny type HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39.